John F. Moore

Leukemia-associated myeloid cells support distinct T-ALL subtypes via unique signals converging on metabolic alterations.

Although intensified chemotherapy regimens have improved survival of T-cell acute lymphoblastic leukemia (T-ALL) patients, treatment-related toxicities and poor outcomes following relapse highlight the need for alternative therapeutics. Our previous studies showed that leukemia-associated myeloid cells support T-ALL pr...